Navigation Links
Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
Date:4/16/2008

HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented data on its novel, proprietary third-generation Hsp90 inhibitors demonstrating a high degree of target specificity, strong binding affinity and potency, a long lifetime in tumor tissue and significant antitumor activity and safety in murine xenograft and orthotopic models.

Hsp90 is a protein chaperone that acts to stabilize and/or activate a number of proteins required for cellular signaling pathways, including several known determinants of carcinogenesis such as HER2 (Erb2), B-Raf, c-Kit, Flt-3 and Raf-1. Hsp90 is effectively inhibited by benzoquinone ansamycins, such as geldanacmycin and its derivatives, which bind to the ATP binding site in the N-terminal domain. Kosan's lead Hsp90 inhibitor, tanespimycin (17-AAG), is a geldanamycin derivative. Kosan's third-generation Hsp90 inhibitors are non-benzoquinone ansamycins that have been genetically engineered to retain a high degree of specificity of tanespimycin for the ATP binding pocket of Hsp90 yet do not rely upon activation of the quinone moiety for maximal inhibitor activity. These third-generation Hsp90 inhibitors are highly potent molecules in tumor models with properties that significantly distinguish them from other Hsp90 inhibitors.

"Kosan's third-generation Hsp90 inhibitors expand our Hsp90 portfolio, and represent opportunities for product diversification and life-cycle extension," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Developing tanespimycin, our first generation Hsp90 inhibitor, in multiple myeloma and in breast cancer, is Kosan's highest priority. We believe that our next-generation molecules add value to our Hsp90 program an
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
2. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
3. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
4. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
5. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
6. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
7. Kosan Announces February 28, 2008 Conference Call and Webcast
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Kosan Announces Third Quarter 2007 Financial Results
10. Kosan to Reacquire Epothilone Program From Roche
11. Kosan Biosciences to Host Research & Development Day on October 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... by allowing for diversity of research,approaches while also encouraging sharing of IP, ... ... to result from reduced complexity, elimination of ... be maintained; South San Francisco,site to operate as an independent research and ...
... ev3 Inc. (Nasdaq:,EVVV) will release its 2008 second quarter ... regular market trading hours., The company will host ... a.m. Central Time (8:30 a.m. Eastern Time). ev3 management ... followed by a,question and answer session., The conference ...
... Apo-Al/HDL drug to be highlighted, TSX Exchange ... Resverlogix Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased ... in an article titled,"Emerging Antidyslipidemic Drugs", which appears ... Drugs, a well respected scientific journal for,the pharmaceutical ...
Cached Biology Technology:Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 2Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 3Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 4Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 5Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 6Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 7Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 8Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 9Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 10Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 11Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 12ev3 Inc. to Report 2008 Second Quarter Financial Results and Host Conference Call on August 1, 2008 2Resverlogix's Lead Drug Featured in Key Scientific Publication 2
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... The Wistar Institute shows how our cells create alternate versions ... genes are associated with multiple gene promoters, the researchers say, ... gene, for example, can be made with the same genetic ... Research, available online now, show how genes are read in ...
... Networks of biologically-connected marine protected areas need to be ... of marine fish larvae that take them from one ... Research published today in the international journal Oecologia sheds ... their larval stages, important information for the effective design ...
... American Association for Cancer Research has been the premier ... This year, Elizabeth H. Blackburn, Ph.D., the immediate ... laureate, will chair the Second AACR Conference on Frontiers ... research leaders from across the globe to encourage and ...
Cached Biology News:Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 2Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 3Data revealing migrations of larval reef fish vital for designing networks of marine protected areas 2
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
... Vybrant Apoptosis Assay Kit #4 ... that occur in the permeability of cell ... both YO-PRO-1 and propidium iodide nucleic acid ... plasma membranes of apoptotic cells and labels ...
Request Info...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
Biology Products: